Ceritinib: a Review in ALK-Positive Advanced NSCLC

Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

(2016) B. Melosky et al.   Current Oncology

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

(2016) Lucio Crinò et al.   JOURNAL OF CLINICAL ONCOLOGY

142PD: The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer

(2016) J. Zhang et al.   Journal of Thoracic Oncology

Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

(2016) Dong-Wan Kim et al.   LANCET ONCOLOGY

FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

(2015) S. Khozin et al.   CLINICAL CANCER RESEARCH

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

(2015) Yvonne Y. Lau et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors

(2015) Makoto Nishio et al.   Journal of Thoracic Oncology

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)

(2015) Anita Kort et al.   PHARMACOLOGICAL RESEARCH

Cost-Effectiveness Of Ceritinib In The Treatment Of Previously Treated Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In The United Kingdom

(2015) Z Zhou et al.   VALUE IN HEALTH

Cost-Effectiveness Of Ceritinib In Previously Treated Patients With Crizotinib In Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In Canada

(2015) Z Zhou et al.   VALUE IN HEALTH

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK

(2015) Diletta Fontana et al.   Cancer Medicine

The Evolution of Therapies in Non-Small Cell Lung Cancer

(2015) Vishal Boolell et al.   Cancers

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) M. Reck et al.   ANNALS OF ONCOLOGY

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

(2014) R. Katayama et al.   CLINICAL CANCER RESEARCH

Ceritinib: First Global Approval

(2014) Sohita Dhillon et al.   DRUGS

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

(2014) Puey Ling Chia et al.   Clinical Epidemiology

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

(2013) Thomas H. Marsilje et al.   JOURNAL OF MEDICINAL CHEMISTRY